Key clinical point: A dose of 300 mg secukinumab was more effective than 150 mg secukinumab, along with a similar safety profile in patients with psoriatic arthritis (PsA), particularly those who had an inadequate response to tumor necrosis factor inhibitors ( anti-TNF-IR).
Major finding: At week 24, 20% or higher improvement in American College of Rheumatology (ACR20) response (odds ratio [OR] 1.41; P = .01) and resolution of dactylitis (OR 1.42; P = .02) was higher with 300 mg vs. 150 mg secukinumab. The proportion of ACR20 responders was higher with 300 mg vs. 150 mg secukinumab in anti-TNF-IR patients at weeks 24 (OR 1.75; P = .01) and 52 (OR 1.66; P = .01). The risk for adverse events was similar with both doses.
Study details: Findings are from a meta-analysis of 6 studies including 3 randomized controlled trials and 1,141 patients with PsA that compared 300 mg secukinumab (n = 461) vs. 150 mg secukinumab (n = 680).
Disclosures: This study did not report any source of funding. The authors declared no conflict of interests.
Source: Zhang KL et al. Clinics (Sao Paulo). 2021 (Sep 20);76:e2820. doi: 10.6061/clinics/2021/e2820.